UK microbiome firm Microbiotica has completed a €60m (£50m) financing round intended to fund its two lead oral live biotherapeutics (LBP) developed to tackle Ulcerative Colitis (UC).
A new study that examined the microbiomes of people living around the world has found that gut bacteria continuously acquire new functionality—depending on host lifestyle and industrialization.
